纤溶酶原激活物抑制物-1基因4G/5G多态性在急性特发性深静脉血栓形成及血栓后残留静脉闭塞中的影响
本研究在中国特发性深静脉血栓形成患者与健康对照中检测纤溶酶原激活物抑制物-1(PAI-1)4G/5G基因型分布,并分析其与治疗后残留静脉闭塞(RVO)的关联。结果显示基因型频率在患者与对照间无显著差异,但随访末不同基因型患者RVO存在显著差异,4G/4G携带者RVO比例最高;非4G携带者接受导管治疗的效果更好。
要点
- PAI-1 4G/5G基因型频率在特发性深静脉血栓患者与健康对照间无显著差异。
- 随访末RVO比例在4G/4G、4G/5G、5G/5G三组间存在显著差异(P<.05)。
- 非4G携带者接受导管治疗的效果优于其他患者(P=.045)。
核心结论
- PAI-1 4G/5G基因型不是中国患者深静脉血栓形成的相关预测因素,但为特发性深静脉血栓后持续性残留静脉闭塞的危险因素。
研究设计与样本
- 研究纳入108例特发性深静脉血栓患者和108例健康对照,采用荧光原位杂交法测定PAI-1 4G/5G基因型。
- 深静脉血栓患者接受导管治疗或仅抗凝治疗,随访期间采用双功超声评估残留静脉闭塞。
- 共86例患者完成超声随访,平均随访13.4±7.2个月。
主要发现
- 108例患者中,4G/4G纯合子32例(29.6%),4G/5G杂合子62例(57.4%),5G/5G纯合子14例(13%)。
- 患者与对照间基因型频率无显著差异。
- 随访末RVO比例在4G纯合子携带者为76.9%、4G/5G杂合子为58.3%、5G纯合子携带者为33.3%,三组间差异有统计学意义(P<.05)。
- 非4G携带者接受导管治疗的效果更好(P=.045)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Plasminogen activator inhibitor-1 (PAI-1) is an important inhibitor of plasminogen activator, but the role of the PAI-1 4G/5G polymorphism in deep vein thrombosis (DVT) has been contradictory. In this study, we investigated the distribution of the PAI-1 4G/5G genotype in Chinese patients with DVT compared with healthy controls and the association between the PAI-1 4G/5G genotype and the persistence of residual venous occlusion (RVO) after different treatments. METHODS: The PAI-1 4G/5G genotype was determined by fluorescence in situ hybridization in 108 patients with unprovoked DVT and 108 healthy controls. The patients with DVT were treated with catheter-based therapy or anticoagulation only. RVO was assessed by duplex sonography during the follow-up. RESULTS: Thirty-two patients (29.6%) were homozygous for 4G (4G/4G), 62 patients (57.4%) were heterozygous for 4G/5G, and 14 patients (13%) were homozygous for 5G (5G/5G). No significant difference in genotype frequency was found between patients with DVT and controls. A total of 86 patients completed follow-up of ultrasound examination with a mean follow-up of 13.4 ±7.2 months. The results of patients with RVO were significantly different between homozygous 4G carriers (76.9%), heterozygous 4G/5G (58.3%), and homozygous carriers of 5G (33.3%) (P <.05) at the end of follow-up. Catheter-based therapy showed a better result in patients who were noncarriers of 4G (P = .045). CONCLUSIONS: The PAI-1 4G/5G genotype was not a relevant predictor for DVT in Chinese patients, but is a risk factor for persistent RVO after idiopathic DVT.
引用
- Li W, Cao S, Liu B, et al. Influence of the 4G/5G polymorphism of plasminogen activator inhibitor-1 gene in acute unprovoked deep vein thrombosis and residual vein thrombosis. J Vasc Surg Venous Lymphat Disord. 2023. PMID: 36907506. doi:10.1016/j.jvsv.2023.02.007
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。